
    
      This study evaluated the safety, tolerability, and potential efficacy of CGF166 and the
      associated delivery procedures in patients with severe-to-profound unilateral or bilateral
      hearing loss. Eligible patients were required to have documented, non-fluctuating hearing
      loss.
    
  